Michael Leuchten
Stock Analyst at Jefferies
(0.35)
# 4,523
Out of 5,099 analysts
525
Total ratings
47.8%
Success rate
-4.1%
Average return
Main Sectors:
Stocks Rated by Michael Leuchten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: AZN AstraZeneca PLC | Maintained: Buy | 17,500p | 13,932p | +25.61% | 111 | Nov 3, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Hold | €46.00 | €52.86 | -12.98% | 98 | Oct 30, 2026 | |
| EPA: SAN Sanofi | Reiterated: Buy | €100.00 | €81.43 | +22.80% | 25 | Oct 30, 2026 | |
| LON: GSK GSK plc | Reiterated: Buy | 2,500p | 1,842p | +35.76% | 51 | Oct 28, 2026 | |
| GSK GSK plc | Downgraded: Hold | $67 → $56 | $49.13 | +13.78% | 5 | Oct 28, 2026 | |
| SWX: NOVN Novartis AG | Reiterated: Hold | CHF 110.00 | CHF 132.60 | -17.04% | 17 | Oct 27, 2026 | |
| SWX: ROP Roche Holding AG | Reiterated: Sell | CHF 250.00 | CHF 396.30 | -36.92% | 73 | Oct 23, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €470.00 | €291.50 | n/a | 42 | Aug 21, 2023 | |
| ETR: MRK Merck KGaA | Reiterated: Buy | €208.00 | €148.20 | n/a | 40 | Aug 4, 2023 | |
| EPA: IPN Ipsen S.A. | Reiterated: Hold | €108.00 → €113.00 | €155.80 | n/a | 11 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €420.00 → €390.00 | €219.80 | n/a | 10 | Jun 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 2,650p | 3,913p | n/a | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $40.45 | n/a | 20 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €400.00 | €229.00 | n/a | 6 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €83.00 → €80.00 | €40.26 | n/a | 4 | Nov 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €40.00 → €45.00 | €48.64 | n/a | 2 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 75.00 → CHF 85.00 | CHF 60.28 | n/a | 6 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $45.55 | n/a | 1 | May 12, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $161.52 | n/a | 2 | Apr 22, 2016 |
AstraZeneca PLC
Nov 3, 2026
Maintained: Buy
Price Target: 17,500p
Current: 13,932p
Upside: +25.61%
Bayer Aktiengesellschaft
Oct 30, 2026
Reiterated: Hold
Price Target: €46.00
Current: €52.86
Upside: -12.98%
Sanofi
Oct 30, 2026
Reiterated: Buy
Price Target: €100.00
Current: €81.43
Upside: +22.80%
GSK plc
Oct 28, 2026
Reiterated: Buy
Price Target: 2,500p
Current: 1,842p
Upside: +35.76%
GSK plc
Oct 28, 2026
Downgraded: Hold
Price Target: $67 → $56
Current: $49.13
Upside: +13.78%
Novartis AG
Oct 27, 2026
Reiterated: Hold
Price Target: CHF 110.00
Current: CHF 132.60
Upside: -17.04%
Roche Holding AG
Oct 23, 2026
Reiterated: Sell
Price Target: CHF 250.00
Current: CHF 396.30
Upside: -36.92%
Sartorius Aktiengesellschaft
Aug 21, 2023
Reiterated: Buy
Price Target: €470.00
Current: €291.50
Upside: n/a
Merck KGaA
Aug 4, 2023
Reiterated: Buy
Price Target: €208.00
Current: €148.20
Upside: n/a
Ipsen S.A.
Jun 30, 2023
Reiterated: Hold
Price Target: €108.00 → €113.00
Current: €155.80
Upside: n/a
Jun 19, 2023
Reiterated: Buy
Price Target: €420.00 → €390.00
Current: €219.80
Upside: n/a
Oct 10, 2022
Reiterated: Buy
Price Target: 2,650p
Current: 3,913p
Upside: n/a
Jun 28, 2022
Downgraded: Sell
Price Target: n/a
Current: $40.45
Upside: n/a
Feb 28, 2022
Reiterated: Sell
Price Target: €400.00
Current: €229.00
Upside: n/a
Nov 4, 2021
Reiterated: Buy
Price Target: €83.00 → €80.00
Current: €40.26
Upside: n/a
Nov 2, 2021
Reiterated: Hold
Price Target: €40.00 → €45.00
Current: €48.64
Upside: n/a
Aug 23, 2021
Reiterated: Buy
Price Target: CHF 75.00 → CHF 85.00
Current: CHF 60.28
Upside: n/a
May 12, 2016
Upgraded: Buy
Price Target: n/a
Current: $45.55
Upside: n/a
Apr 22, 2016
Upgraded: Hold
Price Target: n/a
Current: $161.52
Upside: n/a